Background {#Sec1}
==========

Systemic lupus erythematosus (SLE) is a multisystem, autoimmune, connective-tissue disorder with frequent psychological comorbidities, of which depression and anxiety are two common manifestations \[[@CR1], [@CR2]\]. It has been reported that there were 2 times higher prevalence of depression in SLE patients compared to the general population \[[@CR3]\]. In addition, previous study has reported that the anxiety disorders were twice as prevalent among SLE patients as compared to the controls \[[@CR4]\]. Depression and anxiety often have profound impacts on SLE patients' health and well-being including increased incidence of cardiovascular diseases \[[@CR5]\], myocardial infarction \[[@CR6]\], suicidal ideation \[[@CR7]\], physical disability \[[@CR8]\], decreased quality of life \[[@CR9], [@CR10]\], and a higher risk of premature mortality \[[@CR11]\]. Therefore, depression and anxiety may be useful targets for interventions aimed at improving subjective health and quality of life in individuals with SLE. However, current epidemiological evidence found that the prevalence of depression and/or anxiety in SLE patients ranged widely from 2% to 91.7% in different studies \[[@CR12], [@CR13]\]. This vast inter-study difference was previously attributed to multiple factors, including study quality, unclear definition of depression or anxiety, diverse screening strategies used across studies \[[@CR14]\]. Reliable estimates of depression and anxiety prevalence are important for informing efforts to prevent, treat, and identify causes of depression and anxiety among SLE patients. Recent meta-analyses have estimated the overall prevalence of depression and/or anxiety in rheumatoid arthritis and osteoarthritis patients \[[@CR14], [@CR15]\]. There has only been one previous systematic review of psychiatric symptoms in SLE \[[@CR16]\]; however, no systematic review was conducted to quantify the prevalence of depression and anxiety in SLE using meta-analysis techniques. Our goal was to address this limitation. The objectives of this systematic review were (i) to establish pooled prevalence levels of depression and anxiety among adult SLE patients; (ii) to provide a summary of the methods used to define depression and anxiety in SLE; and (iii) to explore the impacts of study characteristics on prevalence estimates.

Methods {#Sec2}
=======

This systematic review was conducted within the Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement \[[@CR17]\] and followed a predetermined registered protocol (PROSPERO: CRD42016044125).

Search strategy {#Sec3}
---------------

A systematic review of published literature in scientific journals that reported on the prevalence of depression and/or anxiety among SLE patients was conducted by two independent reviewers using the following databases from their inception to August 2016: PubMed, Embase, PsycINFO, and the Cochrane database library. The computer-based searches combined terms related to SLE patients and study design with those related to depression or anxiety (see Additional file [1](#MOESM1){ref-type="media"}). We conducted citation chasing search strategy with all reference lists of included articles and relevant review papers were considered to identify potentially omitted articles. Finally, we corresponded with the authors for further information if we encountered articles just provided the mean and standard deviation of the depression and/or anxiety assessment scale.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies were included if they met the following criteria: (i) cross-sectional design, baseline cross-sectional data from a longitudinal study or baseline cross-sectional data from a trial, before group allocation; (ii) used validated methods (clinical interviews or self-report instruments) to assess depression or anxiety; and (iii) the sample size was no less than 60.

Case reports, review articles, animal studies, studies investigating neuropsychiatric syndromes, studies in languages other than English and papers not dealing with SLE patients were excluded. For this meta-analysis, studies using pediatrics sample or screening tools without stating the cut-off thresholds used to detect depression or anxiety were also excluded. Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"} presented a full list of the eligible methods of detecting depression and anxiety, alongside the numbers of articles utilizing each method and the number of participants assessed.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Two researchers read the relative studies independently by the titles and abstracts to exclude the references which did not met the inclusion criteria. Then, they read full texts in the remaining studies as mentioned above, and determined whether these references included were final studies or not. When multiple publications spanned the years of longitudinal studies, baseline prevalence levels were reported. The following information was independently extracted from each article by other two trained investigators using a standardized form: year, country, mean disease duration, percentage of female participants, sample size, average age of participants, criteria for detection of depression and anxiety, and reported prevalence of depression and/or anxiety. If we encountered multiple publications from the same cohort, we used the data from the most recent or the paper reporting data from the largest number of participants. The methodological quality of each study included in the present meta-analysis was assessed using a modified version of the Newcastle-Ottawa Scale \[[@CR18]\]. Studies were judged to be at low risk of bias (≥3 points) or high risk of bias (\<3 points). Any disagreements in data extraction and quality assessment were resolved through discussion between the two reviewers or adjudication with a third reviewer.

Outcome measures {#Sec6}
----------------

The outcomes were major/minor depression and affective/dysthymic/adjustment/anxiety disorder diagnosed with a structured clinical assessment \[e.g., Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV or International Classification of Diseases (ICD)-10\] or depression and/or anxiety assessed with validated assessment tools \[e.g., the Hospital Anxiety and Depression Scale (HADS), the Centre for Epidemiologic Studies Depression Scale (CES-D)\] (see Additional file [2](#MOESM2){ref-type="media"}).

Statistical analyses {#Sec7}
--------------------

Because random-effects models tended to provide wider confidence intervals (CI) and were preferable in the presence of between-study heterogeneity, we used a random-effects meta-analysis to pool studies reporting the prevalence of depression and/or anxiety in SLE patients \[[@CR19]\]. Between-study heterogeneity was assessed by the I^2^ with thresholds of ≥25%, ≥50% and ≥75% indicating low, moderate and high heterogeneity, respectively \[[@CR20]\]. The influence of individual study on the overall prevalence estimate was explored by serially excluding each study in sensitivity analyses. Wherever possible, subgroup analyses were planned by overall study quality, sample size, country of origin and publication year, if there was more than one study in the subgroup. Pearson's and Spearman's correlation analyses were used to assess the association between variables and prevalence of depression and anxiety in people with SLE. Funnel plots and Egger's test were combined to explore the potential publication bias in this meta-analysis \[[@CR21], [@CR22]\]. Statistical analyses were performed with STATA version 12.0. Statistical tests were 2-sided and used a significance threshold of *P* \< 0.05.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

Fig. [1](#Fig1){ref-type="fig"} provided the details of the study selection process. The initial search identified a total of 3347 potentially relevant articles. After removal of duplicates, titles and then abstracts were screened for potential eligibility. From this, 121 were considered in the full-text review, of which 59 articles met the inclusion criteria, and a full reference list was presented in Additional file [3](#MOESM3){ref-type="media"}. Inter-rater reliability of reviewers regarding study relevancy was high (Kappa = 0.87).Fig. 1Search results and study selection

Study characteristics {#Sec10}
---------------------

A summary of the included study characteristics was shown in Table [1](#Tab1){ref-type="table"}. A total of 59 identified studies matched the inclusion criteria, reporting on a total of 10828 adult SLE patients. Twenty took place in North America, 18 in Asia, 12 in Europe, 6 in South America, 1 in Oceania, and 1 in Africa. The median of mean ages was 39 years (range, 30.0-50.1), and the median percentage of females represented in the sample was 93% (range, 75%--100%). In addition, the median number of participants per study was 100 (range, 60--1827), and the median of mean disease duration was 9 years (range, 0.22--16.3). Depression was defined in 35 different ways (Table [2](#Tab2){ref-type="table"}). Seventeen studies assessed for depression using the 21 Item-Beck Depression Inventory (BDI), with sixteen different thresholds were presented in the articles. Thirteen articles used the CES-D; six different cut-off points were presented, and the most commonly used being 16. Twelve used the HADS with a cutoff of 8 or more, and 6 used other screening tools. Ten studies assessed for major depression using diagnostic criteria (DSM or ICD). The most commonly used screening questionnaire to assess anxiety was the HADS, with 10 studies using this screening tool with thresholds of 8. The methods employed to assess depression and anxiety and the frequency of their use were presented in Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}. When evaluated by Newcastle-Ottawa quality assessment criteria, out of 5 possible points, 2 studies received 5 points, 7 received 4 points, 13 received 3 points, 36 received 2 points, and 1 received 1 point. The details of the assessment of individual studies were shown in Additional file [4](#MOESM4){ref-type="media"}.Table 1Overview of prevalence studies of mood in SLE patients (N ≥ 60)Study IDCountryDisease duration, mean ± SD/median (range)Women, %Sample sizeAge, mean ± SD/median (range), yearsCriteria for detection of anxiety (cutoff)Anxiety prevalence, %Criteria for detection of depression (cutoff)Depression prevalence, %NOSAbdul-Sattar 2015Egypt10.0 ± 4.6 years95%8030.9 ± 11.7CES-D (\>16.7)43.752Appenzeller 2009Brazil64.5 ± 48.5 months94.6%16732.1 ± 11.021 Item-BDI (≥10)20.92Bachen 2009USA15.4 ± 9.7 years100%32647.9 ± 11.3DSM-IV64DSM-IVMajor depressive disorder: 42.4, dysthymic disorder: 2.95Bogdanovic 2015Serbia6.8 ± 2.9 years100%6043.4 ± 12.821 Item-BDI (≥16/≥20/≥30)91.7/70/3.32Calderon 2014ChileMedian: 32.0 (0--243.0) months100%82Median: 36.0 (17.0--64.0)HADS (≥8)372Cho 2014South KoreaNS90.1%20141.3 ± 13.2CES-D (≥16)39.33Chin 1993Malaysia4.1 ± 3.5 years95%7931.1 ± 9.1ICD-9 and DSM-III7.6ICD-9 and DSM-IIIMajor depressive disorder: 6.3, dysthymic disorder: 32.92Da Costa 2005Canada13.8 ± 10.1 years100%10045.4 ± 14.0CES-D (≥16)313Doria 2004Italy9.9 ± 6.3 years87.3%12638.9 ± 11.9HAS (≥6/≥15)74.6/27HDS (≥8/≥16)40.5/2.42Duvdevany 2011Israel11.4 ± 9.1 years88%10037.0 ± 11.8HADS (≥8)20HADS (≥8)374García-Carrasco 2011Mexico106.5 ± 85.5 months100%10640.5 ± 12.0CES-D (≥16)38.82García-Carrasco 2013Mexico10.5 ± 7.4 years100%10543.6 ± 11.3CES-D (≥16)332Greco 2009USA16.3 ± 7.0 years100%16150.1 ± 10.0CES-D (≥16)272Hanly 2015Canada5.6 ± 4.8 years88.9%182735.1 ± 13.3DSM-IV12.74Harrison 2006USA15.3 ± 3.2 years100%9343.3 ± 13.7CES-D (\>27)16.12Huang 2007China7.5 ± 6.9 years91.5%12937.4 ± 10.7HADS (≥8)32HADS (≥8)202Iverson 2002CanadaNSNS103NS21 Item-BDI (≥17)39.81Jarpa 2011ChileMedian: 5.0 (0.1--40.0) years90.8%87Median: 39.0 (16.0--27.0)DSM-IV18.1DSM-IVMajor depressive disorder: 21.7, dysthymic disorder: 4.82Julian 2011USA15.8 ± 9.3 years93%15048.8 ± 12.3ICD-10 and DSM-IVMajor depressive disorder: 17, dysthymic disorder: 4, minor depression: 63Jung 2015Korea6.8 ± 4.4 years93%10040.6 ± 10.321 Item-BDI (≥21)132Katz 2011USA13.6 ± 8.5 years100%71648.1 ± 12.6CES-D (≥24)253Karol 2013USANS93%12738.1 ± 12.321 Item-BDI (≥18)41.72Karimifar 2013Iran4.1 ± 0.5 years80%10034.8 ± 10.921 Item-BDI (≥14)602Kheirandish 2015Iran9.0 ± 7.7 years92.2%16633.1 ± 11.1Cattell questionnaire (≥21)84.921 Item-BDI (≥5/≥30)64.5/92Kotsis 2014Greece13.2 ± 9.1 years84%7544.1 ± 13.3PHQ-9 (≥10)29.32Kim 2015USA12.0 ± 8.0 years93%8939.0 ± 15.0CES-D (≥16)633Lapteva 2006USA13.8 ± 10.2 years75%6041.0 ± 13.0DSM-IVMajor depressive disorder: 16.62Lisitsyna 2014NS134.9 ± 8.8 months85.6%18034.6 ± 0.93ICD-10Major depressive disorder: 24.4, dysthymic disorder: 25.6, adjustment disorders: 18.92Mak 2011Singapore54.9 ± 70.7 months88%6040.5 ± 12.9HADS (≥8)38HADS (≥8)222Maneeton 2013Thailand6.1 ± 4.8 years98%6231.8 ± 9.0HAS (≥14)37.1HDS (≥11)45.22Mirbagher 2016Iran8.3 ± 3.8 years100%7736.5 ± 10.1HADS (≥8)71.4HADS (≥8)46.13Monaghan 2007Australia10.2 ± 8.7 years97%6044.4 ± 12.2HADS (≥8)44HADS (≥8)363Montero-Lo'pez 2016Spain0.2 ± 0.7 years100%9738.6 ± 9.3SCL-90-R4.1SCL-90-R5.22Nery 2008Brazil9.8 ± 6.5 years100%7134.8 ± 10.1SCID for DSM-IV46.5SCID for DSM-IVMajor depressive disorder: 40.82Neville 2014Canada10.2 ± 9.5 years92.4%61246.8 ± 16.7PHQ-2 (≥3)28.14Palagini 2014Italy15.0 ± 8.0 years100%8143.6 ± 11.2SAS (\>44)17.321 Item-BDI (≥11)34.63Panopalis 2010USA13.8 ± 8.9 years91%80747.6 ± 13.1CES-D (≥16)38.55Pettersson 2015SwedenMedian: 12.0 years92%305Median: 48HADS (≥8)34HADS (≥8)514Postal 2016BrazilMedian: 9.0 (0--33.0) years96.7%153Median: 30.0 (10.0--62.0)21 Item-BAI (≥8/≥16/≥26)60.7/43.1/18.321 Item-BDI (≥14/≥20/≥29)45.7/30.7/18.92Radhakrishan 2011IndiaNS100%10018-60SCID for DSM-IV51SCID for DSM-IVMajor depressive disorder: 46, adjustment disorder: 21, dysthymic disorder: 92Roebuck-Spencer 2006USA13.8 ± 10.2 years80%6041.3 ± 12.821 Item-BDI (≥14)202Segal 2012USA12.0 ± 2.3 years93%7141.7 ± 1.5CES-D (≥16)392Sehlo 2013Saudi Arabia6.9 ± 4.2 years100%8034.8 ± 11.2SCID for DSM-IVMajor depressive disorder: 11.252Sfikakis 1998Greece7.8 ± 6.4 years91.5%7137.0 ± 13.0HAS (\>17)23.9HDS (\>17)19.72Shakeri 2015IranNS92.5%16030.1 ± 6.221 Item-BAI (≥8/≥16/≥26)81.2/51.9/18.121 Item-BDI (≥21/≥31/\>40)69.3/38.7/20.62Shen 2015ChinaNS91.2%15632.9 ± 10.2Zung SAS (≥50)20.51Zung SDS (≥53)33.333Skare 2014Brazil8.2 ± 6.9 years93%10039.2 ± 12.521 Item-BDI\
(≥19/≥ 30)21/22Shorta1l 1995England11.0 ± 7.1 years95%8041.0 ± 11.2HADS (≥8)39HADS (≥8)262Stoll 2001Switzerland11.4 ± 9.0 years90%6044.5 ± 15.4HADS (≥8)163Tam 2008China9.7 years95.9%29142.0 ± 12.0HADS (≥8)22HADS (≥8)18.23Tay 2015Singapore72.3 ± 81.1 months86.4%11038.7 ± 12.6HADS (≥8)40.9HADS (≥8)15.52Tench 2000EnglandMedian: 36.0 (12.0--79.5) months100%120Median: 38.0 (32.0--45.0)HADS (≥8)60HADS (≥8)372Tjensvoll 2010Norway12.3 ± 8.6 years87%6343.4 ± 13.321 Item-BDI\
(≥13)23.82Utset 2014USAMedian: 9 years95%344\>18CES-D (\>10)54.54van Exel 2013Netherlands7.8 ± 7.0 years88.2%10244.4 ± 12.521 Item-BDI\
(≥14)273Vina 2015USA143.2 ± 117.8 months93%34344.4 ± 12.9CES-D (≥17)47.24Weder-Cisneros 2004USAMean: 97.0 (6--348) months91.4%8131.2 ± 9.721 Item-BDI\
(≥14)40.73Xie 2012ChinaMedian: 1.3 years93.7%28534.0 ± 13.021 Item-BDI\
(≥5/14/≥21)59.3/40.7/19.34Zakeri 2012IranNS90.5%71\>1821 Item-BDI\
(≥16/≥32)60/9.42*NS* not stated, *CES-D* Centre for Epidemiological Studies Depression Scale, *BDI* Beck Depression Inventory, *BAI* Beck Anxiety Inventory, *DSM-III/IV* Diagnostic and Statistical Manual of Mental Disorders, Third/Fourth Edition, *HADS* Hospital Anxiety and Depression Scale, *ICD* International Classification of Diseases, *HAS* the Hamilton Anxiety Scale, *HDS* the Hamilton Depression Scale, *PHQ* Patient Health Questionnaire, *SCID* Structured Clinical Interview for Diagnostic and Statistical Manual, *SCL-90-R* Symptoms Checklist-90-Revised, *Zung SAS* Zung Self-rating Anxiety Scale, *Zung SDS* Zung Self-rating Depression Scale Table 2Methods of detecting depression and summary of prevalence and heterogeneity findingsToolDefinition/cutoffNo. of studiesNo. of participantsPrevalence, % (95% CI)Heterogeneity I^2^, %DSM and/or ICDMajor depressive disorder10296024 (16, 31)95.2Dysthymic disorder692212 (5, 18)93.4Adjustment disorder228020 (15, 24)0.0Minor depression11506 (2, 10)-HADS≥812147430 (22, 38)91.6CES-D\>10134455 (49, 60)-≥168164038 (32, 44)81.3\>16.718044 (33, 55)-≥17134347 (42, 52)-≥24171625 (22, 28)-\>2719316 (9, 24)-21 Item-BDI≥5245161 (56, 66)17.7≥10116721 (15, 27)-≥1118135 (24, 45)-≥1316324 (13, 34)-≥14678139 (29, 49)88.2≥16213176 (45, 107)95.4≥17110340 (30, 49)-≥18112742 (33, 50)-≥19110021 (13, 29)-≥20221350 (12, 89)96.8≥21354534 (2, 65)98.8≥29115319 (13, 25)-≥3033265 (0, 9)72.1≥31116039 (31, 46)-≥321719 (3, 16)-\>40116021 (14, 27)-HDS≥8112641 (32, 49)-≥1116245 (33, 58)-≥1611262 (0, 5)-\>1717120 (10, 29)-PHQ-9≥1017529 (19, 40)-PHQ-2≥3161228 (25, 23)-SCL-90-R1975 (1, 10)-Zung SDS≥53115633 (26, 41)-*DSM* Diagnostic and Statistical Manual of Mental Disorders, *ICD* International Classification of Diseases, *HADS* Hospital Anxiety and Depression Scale, *CES-D* Centre for Epidemiological Studies Depression Scale, *BDI* Beck Depression Inventory, HDS Hamilton Depression Scale, *PHQ* Patient Health Questionnaire, *SCL-90-R* Symptoms Checklist-90-Revised, *Zung SDS* Zung Self-rating Depression Scale Table 3Methods of detecting anxiety and summary of prevalence and heterogeneity findingsToolDefinition/cutoffNo. of studiesNo. of participantsPrevalence, % (95% CI)Heterogeneity I^2^, %DSM and/or ICD for anxiety disorder566337 (12, 63)98.3HADS≥810133240 (30, 49)93.021 Item-BAI≥8231371 (51, 91)94≥16231348 (39, 56)59.2≥26231318 (14, 22)0HAS≥6112675 (67, 82)-≥1416237 (25, 49)-≥15112627 (19, 35)-\>1717124 (14, 34)-Cattell questionnaire≥21116685 (79, 90)-SCL-90-R1974 (0, 8)-Zung SAS\>4418117 (9, 26)-≥50115621 (14, 27)-*DSM* Diagnostic and Statistical Manual of Mental Disorders, *ICD* International Classification of Diseases, *HADS* Hospital Anxiety and Depression Scale, *BAI* Beck Anxiety Inventory, *HAS* Hamilton Anxiety Scale, *SCL-90-R* Symptoms Checklist-90-Revised, *Zung SAS* Zung Self-rating Anxiety Scale

Prevalence of depression among SLE patients {#Sec11}
-------------------------------------------

Prevalence estimates of depression ranged from 2% to 91.7% in individual studies (Table [1](#Tab1){ref-type="table"}). Table [2](#Tab2){ref-type="table"} indicated the summary of meta-analyses and heterogeneity assessments. Meta-analyses revealed the prevalence of major depressive disorder to be 24% (95% CI, 16%--31%) according to the DSM and/or ICD diagnostic criteria, with high heterogeneity (I^2^ = 95.2%). Prevalence estimates of depression were 30% (95% CI, 22%--38%, I^2^ = 91.6%) for the HADS with thresholds of 8 and 38% (95% CI, 32%--44%, I^2^ = 81.3%) for the CES-D with thresholds of 16, respectively. Prevalence of depression according to the 21 Item-BDI with a cutoff of 14 or more was 39% (95% CI, 29%--49%), with high heterogeneity (I^2^ = 88.2%) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Prevalence of depressive disorder in SLE

Prevalence of anxiety among SLE patients {#Sec12}
----------------------------------------

Prevalence of anxiety alone ranged between 4% and 85% in individual studies (Table [1](#Tab1){ref-type="table"}). Table [3](#Tab3){ref-type="table"} presented the summary of meta-analyses and heterogeneity assessments. Meta-analyses pooled the prevalence of anxiety to be 40% (95% CI, 30%--49%, I^2^ = 93.0%) and 37% (95% CI, 12%--63%, I^2^ = 98.3%) according to the HADS with thresholds of 8 and the DSM and/or ICD diagnostic criteria, respectively (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Prevalence of anxiety in SLE

Sensitivity and subgroup analyses {#Sec13}
---------------------------------

Table [4](#Tab4){ref-type="table"} suggested depression and anxiety prevalence estimates according to each sensitivity and subgroup analysis, in comparison with the primary analysis. Sensitivity analyses revealed that the exclusion of studies with less sample representativeness tended to decrease dysthymic disorder prevalence estimates according to DSM and/or ICD. The removal of studies with less comparable respondent and non-respondent comparability tended to increase depression prevalence estimates according to the HADS with a cutoff of 8 or more. According to DSM and/or ICD, anxiety prevalence estimates had a trend to decrease by exclusion of studies only using female sample. The subgroup analyses were conducted according to sample size, overall quality, publication year, and country of origin. The results showed that studies with sample size \<200 had higher anxiety estimates \[43% (95% CI, 31%--55%) vs 28% (95% CI, 16%--40%)\] according to the HADS with a cutoff of 8 or more. When evaluated by Newcastle-Ottawa criteria, studies with lower total overall quality scores yielded higher dysthymic disorder estimates \[18% (95% CI, 6%--29%) vs 3% (95% CI, 2%--25%)\] according to DSM and/or ICD. In contrast with clinical interviews (DSM and/or ICD), more recent publications tended to yield higher depression and anxiety prevalence estimates according to self-report instruments. The subgroup analyses for country of origin showed no clear patterns. There was no particular trend or pattern in any other sensitivity analyses or subgroup analyses.Table 4Impact of study characteristics on prevalence estimates for depression and anxiety in SLE: sensitivity and subgroup analysesDepression definition (cutoff)Anxiety definition (cutoff)Major depressive disorder (DSM and/or ICD)Dysthymic disorder (DSM and/or ICD)HADS (≥8)CES-D (≥16)21 Item-BDI (≥14)21 Item-BDI (≥21)21 Item-BDI (≥30)HADS (≥8)Anxiety disorder\
(DSM and/or ICD)Primary analysis24 (16, 31)\
I^2^ = 95.2%\
10 studies\
2960 patients12 (5, 18)\
I^2^ = 93.4%\
6 studies\
922 patients30 (22, 38)\
I^2^ = 91.6%\
12 studies\
1474 patients38 (32, 44)\
I^2^ = 81.3%\
8 studies\
1640 patients39 (29, 49)\
I^2^ = 88.2%\
6 studies\
781 patients34 (2, 65)\
I^2^ = 98.8%\
3 studies\
545 patients5 (0, 9)\
I^2^ = 72.1%\
3 studies\
326 patients40 (30, 49)\
I^2^ = 93.0%\
10 studies\
1332 patients37 (12, 63)\
I^2^ = 98.3%\
5 studies\
663 patientsSensitivity analysesExcluding studies with less sample representativeness24 (6, 42)\
I^2^ = 98.2%\
3 studies\
2303 patients3 (2, 5)\
I^2^ = 0%\
2 studies\
476 patients29 (15, 44)\
I^2^ = 82.7%\
3 studies\
220 patients-36 (27, 45)\
I^2^ = 72.4%\
3 studies\
468 patients\--31 (8, 55)\
I^2^ = 90.1%\
2 studies\
160 patients-Excluding studies with less comparable respondent and non-respondent comparability\--45 (37, 54)\
I^2^ = 68.1%\
3 studies\
482 patients44 (29, 59)\
I^2^ = 91.9%\
3 studies\
996 patients\-\--42 (17, 66)\
I^2^ = 96.9%\
3 studies\
482 patients-Excluding studies\
only using female sample16 (11, 21)\
I^2^ = 79.8%\
6 studies\
2383 patients16 (4, 28)\
I^2^ = 95.0%\
4 studies\
496 patients27 (17, 36)\
I^2^ = 92.9%\
9 studies\
1195 patients44 (35, 54)\
I^2^ = 85.6%\
4 studies\
1168 patients39 (29, 49)\
I^2^ = 88.2%\
6 studies\
781 patients34 (2, 65)\
I^2^ = 98.8%\
3 studies\
545 patients5 (−2, 12)\
I^2^ = 85.9%\
2 studies\
266 patients33 (27, 39)\
I^2^ = 79.4%\
8 studies\
1135 patients12 (2, 23)\
I^2^ = 76.5%\
2 studies\
166 patientsSubgroup analysesSample size\<20022 (14, 31)\
I^2^ = 90.5%\
8 studies\
807 patients14 (5, 23)\
I^2^ = 93.3%\
5 studies\
596 patients29 (22, 36)\
I^2^ = 81.1%\
10 studies\
878 patients38 (28, 48)\
I^2^ = 86.3%\
6 studies\
1008 patients39 (25, 52)\
I^2^ = 90.5%\
5 studies\
496 patients41 (−14, 96)\
I^2^ = 99.2%\
2 studies\
260 patients5 (0, 9)\
I^2^ = 72.1%\
3 studies\
326 patients43 (31, 55)\
I^2^ = 91.8%\
8 studies\
736 patients30 (9, 52)\
I^2^ = 96.0%\
4 studies\
337 patients≥20027 (2, 57)\
I^2^ = 99.1%\
2 studies\
2153 patients-35 (2, 67)\
I^2^ = 98.8%\
2 studies\
596 patients39 (36, 42)\
I^2^ = 0.0%\
2 studies\
632 patients\-\--28 (16, 40)\
I^2^ = 90.8%\
2 studies\
596 patients-Overall quality\<3 points (low quality)23 (13, 34)\
I^2^ = 91.8%\
7 studies\
657 patients18 (6, 29)\
I^2^ = 93.2%\
4 studies\
446 patients26 (18, 33)\
I^2^ = 77.5%\
6 studies\
581 patients34 (28, 40)\
I^2^ = 45.5%\
4 studies\
443 patients42 (21, 63)\
I^2^ = 93.8%\
3 studies\
313 patients41 (−14, 96)\
I^2^ = 99.2%\
2 studies\
260 patients5 (0, 9)\
I^2^ = 72.1%\
3 studies\
326 patients42 (32, 52)\
I^2^ = 82.5%\
5 studies\
499 patients30 (9, 52)\
I^2^ = 96.0%\
4 studies\
337 patients≥3 points (high quality)26 (6, 42)\
I^2^ = 98.2%\
3 studies\
2303 patients3 (2, 5)\
I^2^ = 0%\
2 studies\
476 patients34 (20, 48)\
I^2^ = 95.0%\
6 studies\
893 patients42 (33, 52)\
I^2^ = 87.9%\
4 studies\
1197 patients36 (27, 45)\
I^2^ = 72.4%\
3 studies\
468 patients\--38 (23, 53)\
I^2^ = 95.5%\
5 studies\
833 patients-Publication year1990s\-\-\-\-\-\-\-\--2000s33 (17, 50)\
I^2^ = 91.0%\
3 studies\
457 patients-25 (17, 33)\
I^2^ = 81.3%\
5 studies\
660 patients28 (23, 34)\
I^2^ = 0.0%\
2 studies\
261 patients30 (10, 51)\
I^2^ = 86.8%\
2 studies\
141 patients\--39 (22, 57)\
I^2^ = 95.0%\
4 studies\
600 patients56 (39, 73)\
I^2^ = 86.3%\
2 studies\
397 patients2010-21 (14, 29)\
I^2^ = 91.5%\
6 studies\
2424 patients11 (2, 19)\
I^2^ = 92.0%\
4 studies\
517 patients35 (22, 48)\
I^2^ = 93.1%\
6 studies\
734 patients42 (35, 48)\
I^2^ = 78.6%\
6 studies\
1379 patients43 (32, 55)\
I^2^ = 88.5%\
4 studies\
640 patients34 (2, 65)\
I^2^ = 98.8%\
3 studies\
545 patients5 (0, 9)\
I^2^ = 72.1%\
3 studies\
326 patients41 (26, 56)\
I^2^ = 93.8%\
5 studies\
652 patients34 (2, 67)\
I^2^ = 96.1%\
2 studies\
187 patientsCountry of originNorth America22 (8, 37)\
I^2^ = 97.3%\
4 studies\
2363 patients3 (2, 5)\
I^2^ = 0%\
2 studies\
476 patients-38 (31, 45)\
I^2^ = 83.9%\
7 studies\
1439 patients30 (10, 51)\
I^2^ = 86.8%\
2 studies\
141 patients\-\-\--Asia21 (0, 41)\
I^2^ = 96.0%\
3 studies\
259 patients21 (−3, 44)\
I^2^ = 93.7%\
2 studies\
179 patients26 (18, 34)\
I^2^ = 85.4%\
6 studies\
767 patients-50 (31, 69)\
I^2^ = 91.3%\
2 studies\
385 patients34 (2, 65)\
I^2^ = 98.8%\
3 studies\
545 patients-37 (23, 51)\
I^2^ = 94.4%\
6 studies\
767 patients29 (−13, 72)\
I^2^ = 98.2%\
2 studies\
179 patientsEurope\--33 (17, 49)\
I^2^ = 93.8%\
4 studies\
565 patients\-\-\--44 (28, 61)\
I^2^ = 91.9%\
3 studies\
505 patients-South America31 (12, 50)\
I^2^ = 85.3%\
2 studies\
158 patients\-\-\-\-\-\--32 (4, 60)\
I^2^ = 93.5%\
2 studies\
158 patientsThe first line in each set of data is percentage prevalence (95% CI)*DSM* Diagnostic and Statistical Manual of Mental Disorders, *ICD* International Classification of Diseases, *HADS* Hospital Anxiety and Depression Scale, *CES-D* Centre for Epidemiological Studies Depression Scale, *BDI* Beck Depression Inventory

Associated study variables {#Sec14}
--------------------------

We used Pearson's and Spearmen's correlation analyses to assess the association between variables including mean/medium disease duration, proportion of female participants, mean/medium age, representativeness, sample size, comparability, overall quality, country of origin, publication year, and the prevalence of depression and anxiety. Table [5](#Tab5){ref-type="table"} indicated that more recent publications was significantly associated with increased depression prevalence (*r* = 0.26, *P* = 0.04). No study characteristics presented a significant association with anxiety prevalence estimate.Table 5Pearson\'s and Spearmen's correlation between study characteristics and prevalence estimatesStudy characteristicDepression prevalence estimateAnxiety prevalence estimateNo. of studies*rP*No. of studies*rP*Female, %590.030.84240.070.76Mean/medium age, year55−0.130.3523−0.180.94Mean/medium disease duration, year53−0.070.64210.240.29Representativeness590.030.85240.080.70Sample size590.120.38240.010.97Comparability590.240.0724−0.110.61Overall quality590.130.3324−0.100.64Country of origin590.010.9224−0.100.63Publication year590.26^\*^0.0424−0.040.84^\*^Significant at a *P* \<0.05 level

Assessment of publication bias {#Sec15}
------------------------------

Assessment of publication bias indicated significant publication bias, according to the Egger's test, in studies reporting depression according to HADS with thresholds of 8 and CES-D with a cutoff of 16 or more \[Egger: bias = 0.81 (95% CI: 0.04, 1.58), *P* = 0.04, and Egger: bias = 2.79 (95% CI: 0.61, 4.97), *P* = 0.02, respectively\]. There was no significant evidence of publication bias in any other analyses (see Additional file [5](#MOESM5){ref-type="media"}).

Discussion {#Sec16}
==========

This systematic review and meta-analysis of 59 studies involving 10828 adult SLE patients demonstrated that a few studies using gold standard clinical interviews (DSM and/or ICD) reported that major depression and anxiety were presented in 24% and 37% among SLE patients, respectively. The majority of studies using screening tools found that significant depression were presented in 30% using the HADS a cutoff of 8 or more and 39% using the 21 Item-BDI with thresholds of 14. This study also found that more recent publications was significantly associated with increased depression prevalence among SLE patients. Furthermore, the prevalence of anxiety was 40% according to the HADS with thresholds of 8. These prevalence estimates are significantly higher than those observed in the general population \[[@CR23], [@CR24]\] and other rheumatic and connective tissue diseases \[[@CR15], [@CR25], [@CR26]\]. Furthermore, these findings demonstrated that SLE patients tended to have a higher prevalence of anxiety than depression, which was in line with previous studies \[[@CR27], [@CR28]\]. Such discrepancy could be explained by the differences in time frames when these studies were performed, disease characteristics, social and cultural contexts of the lupus patients and tools used for assessing depression or anxiety. Because the development of depression and/or anxiety could result in increased incidence of cardiovascular diseases \[[@CR5]\], decreased quality of life \[[@CR9], [@CR10]\], and a higher risk of premature mortality \[[@CR11]\] among SLE patients, these findings highlighted an important issue in health education for this population.

Neuropsychiatric (NP) disorders appeared in about 70% of the patients diagnosed with SLE \[[@CR29]\]. Previous meta-analyses have assessed the prevalence of the 19 NP syndromes defined by the American College of Rheumatology (ACR) in 1999 among SLE patients \[[@CR30]\]. However, there were a wide variety of neurologic and psychiatric manifestations of SLE, which extended beyond those identified in the 1999 ACR classification criteria for SLE \[[@CR31]\]. Several attempts have been made to devise a classification of NP-SLE manifestations because there were controversies regarding the inclusion of mood disorders in the 1999 ACR NP-SLE criteria \[[@CR31], [@CR32]\]. That's why we excluded the studies investigating neuropsychiatric syndromes among SLE patients in this meta-analysis.

Although studies varied widely in terms of quality, our sensitivity analyses suggested that depression and/or anxiety prevalence estimates (except dysthymic disorder estimates) were reasonably stable. Variation in study sample size contributed importantly to the observed heterogeneity in the data. Studies with sample size \<200 had higher anxiety estimates according to the HADS with thresholds of 8. Furthermore, studies with lower total overall quality scores yielded higher dysthymic disorder estimates according to DSM and/or ICD. Country, publication year, age, and gender also contributed to the heterogeneity between studies.

In this meta-analysis, many methods were used for data extraction and synthesis. The gold standard method was diagnostic interviews using DSM or ICD criteria, which were often time consuming and expensive. Therefore, it was not ideal for examining patients in a busy hospital environment \[[@CR33]\]. Alternatively, self-report screening tools might be used, because they were quick and easy to complete and cheaper to use than diagnostic interviews. However, prevalence estimates using screening tools were often overestimated, because such tools tended to prioritize sensitivity over specificity \[[@CR33]\]. Furthermore, there have not been validation studies to determine the best cut-point for screening tools in SLE patients, and several cut-off scores on self-report tools were often used in many studies. It indicated that the rheumatologists should always report prevalence at conventional cut-points, and screen for depression and anxiety among SLE patients according to the social and cultural contexts of the rheumatologists and SLE patients in clinical practice.

There are, however, additional important shortcomings in the evidence on prevalence of depression in SLE that need to be addressed. First, a substantial amount of the heterogeneity among the studies remained unexplained by the variables examined. Unexamined factors, such as gender, age, disease duration, might contribute to the risk for depression and/or anxiety symptom among SLE patients. Second, the data were derived from studies that used different designs and involved different groups of patients (e.g., from different countries), which might result in heterogeneity among the studies. Third, we did not look for healthy subjects in each study reporting the prevalence of depression or anxiety in SLE patients, which should be addressed in future research.

Conclusions {#Sec17}
===========

The prevalence of depression and anxiety was high in adult SLE patients. It indicated that rheumatologists should screen for depression and anxiety in their patients, and they should refer them to mental health providers in order to identify effective strategies for preventing and treating depression and anxiety among SLE patients.

Additional files {#Sec18}
================

Additional file 1:Search Terms. (DOCX 10 kb) Additional file 2:Summaries of symptom thresholds required for diagnosis of depression/anxiety. (DOCX 19 kb) Additional file 3:The list of 59 studies included in the meta-analysis. (DOCX 19 kb) Additional file 4:Quality Assessment. (DOCX 19 kb) Additional file 5:Assessment of Publication Bias. (DOCX 56 kb)

We would like to thank Chenlin Zhang and Alick for their great assistance with this study.

Funding {#FPar1}
=======

This work was supported by the Natural Science Foundation of China (Grant no. 81401124); the Humanistic Nursing Care Foundation of China (Grant no. RW2016AM14); Preventive Medicine Projects from Bureau of Jiangsu Province (Y2012083); "Top Six Types of Talents" Financial Assistance of Jiangsu Province (Grant no. 10.WSN016); Jiangsu Provincial Commission of Health and Family Planning Foundation (Grant no. Z201622); Science Foundation of Nantong City (Grant no. MS22015003); the College graduate research and innovation of Jiangsu Province (KYZZ15_0353); and the Nantong University Graduate Innovation Program (YKC15075).

Availability of data and materials {#FPar2}
==================================

The majority of data generated or analyzed during this study are included in this published article (and its Additional files). Remaining data not published here are available from the corresponding author on reasonable request.

Authors' contributions {#FPar3}
======================

LZ and TF searched and checked the databases according to the inclusion and exclusion criteria, extracted the data and assessed their quality. LZ analyzed the data and wrote the draft of the paper. RY, QZ and BS gave advice on meta-analysis methodology and revised the paper. All authors contributed to reviewing or revising the paper. BS is the guarantor of this work and had full access to all the data in the study and takes responsibility for its integrity and the accuracy of the data analysis. All authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declared that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

Ethical approval and consent to participate are not required for this review.
